Objective: Little is known about the temporal impact of the rapid scale-up of large antiretroviral therapy (ART) services on programme outcomes. We describe patient outcomes [mortality, loss-to-follow-up (LTFU) and retention] over time in a network of South African ART cohorts.
Introduction
South Africa has the largest antiretroviral therapy (ART) programme in the world [1] . Between 2004 (the start of the national ART programme) and 2007, an estimated 370 000 people initiated treatment in the public sector [2] . But, despite the scope and rapid growth of this programme there are no data on programme outcomes at a national level. The International Epidemiologic Databases to Evaluate AIDS collaboration of Southern Africa (IeDEA-SA) has assembled a series of HIV treatment cohorts from across the country that include approximately 10% of all adults who initiated public sector ART in South Africa by the end of 2007. The aim of this paper is to describe trends in mortality, loss-tofollow-up (LTFU) and programme retention of these adult patients over the first 5 years of the country's national ART programme.
Methods
Study design, population and eligibility criteria The South African cohorts of IeDEA-SA have been described in detail elsewhere [3] . Briefly, the collaboration includes eight adult cohorts providing ambulatory ART services located in the four largest provinces in the country (Western Cape, Free State, Gauteng and Kwazulu-Natal). This analysis included all HIV-positive adults (16 years) who initiated ART in these cohorts between 2002 and 2007.
Variables and definitions
Baseline characteristics included demographics (age, sex), available measures of disease severity (CD4 cell count, WHO stage and viral load) and calendar year of ART initiation. Outcome measures were mortality, LTFU and programme retention. Deaths and transfers were defined by active or passive follow-up at site level. Patients were defined as LTFU if their last patient contact was more than 6 months before the date of closure of the cohort database and were censored at their last contact date. Patients who were transferred out were censored at the transfer date. For patients who started ART but had no further contact with the clinic, 1 day of follow-up was added to allow their inclusion in survival analyses. Programme retention was defined as those who were enrolled and not dead or LTFU at analysis closure. 
Analysis
Baseline characteristics were described with summary statistics (medians, interquartile ranges and proportions). Because of variability in the completeness of baseline data, patient numbers are reported for each analysis. Mean age, median CD4 cell count and proportion in WHO Stage IV were calculated by year of enrolment. Temporal trends were tested with the nonparametric test for trend across continuous variables (age and CD4 cell count). Differences between proportions were tested with the chisquare test. Time to death, LTFU and overall programme retention were analysed using Kaplan-Meier methods and presented by year of enrolment.
Separate proportional hazards regression models, stratified by cohort, were used to assess crude and adjusted associations between patient characteristics and different outcomes. We modelled the proportional hazards of death separately for different time periods as the risk factors for Over the same period, among patients with baseline WHO staging, the proportion of patients with Stage IV disease decreased from 50 to 28% (P < 0.001).
Between 2002/2003 and 2006, 12-month reported mortality declined from 9 to 6% (P < 0.001) ( Table 2 , , and 12-month programme retention declined from 90 to 82% over the same period (P < 0.001) ( Table 2 ). The crude effect of calendar year persisted over 5 years of follow-up ( Fig. 1a-c ).
LTFU increased with duration on treatment ( Table 3 , Fig. 1b ) and made an increasing contribution to overall patient attrition. At 6 months on ART, one-third of the losses to programme were due to mortality: 5% of patients had died while 9% were LTFU. By 36 months, mortality accounted for one-quarter of patient losses: 10% were dead and 30% were LTFU. Overall programme retention dropped from 86% at 6 months to 71% at 24 months and 64% at 36 months.
Associations with baseline characteristics
In all time periods, there was a slight increase in the crude and adjusted risk of death for older patients [adjusted hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.02-1.04, Patient retention is a vital measure of the effectiveness of ART services [6, 7] . Retention in long-term care is complex, especially in low-income and middle-income countries [8] [9] [10] , but not a new issue: primary healthcare services have long faced the problem of patient attrition in providing care for chronic diseases [6, 11] . A systematic review of ART programmes in sub-Saharan Africa found large variation in patient retention across programmes, ranging from 46 to 85% after 2 years on ART [12] . At the start of the South African national programme, based on experience with other chronic diseases, it was suggested that the ART service might retain 60-80% of patients annually [11] . Retention in the earlier years of the programme exceeded this expectation: at 2 years, 71% of all patients were still known to be in care, but the steady increase in attrition during the first 12 months on ART in successive years of enrolment is cause for concern.
Mortality is one reason for patient attrition: in this cohort, observed mortality at 12 months was 6.6%, which is comparable with results from other developing countries [13] . With successive years of enrolment, 12-month mortality decreased. This may be a true decline due to improved coverage of services and patients enrolling with less advanced HIV disease [14] . It is also plausible that as a programme expands, its ability to accurately ascertain patient deaths deteriorates, and high observed LTFU may be associated with poor mortality ascertainment [15] . It is likely that our study, based on routine surveillance, underestimates true mortality in these cohorts. Recent corrected mortality estimates for single South African ART cohorts (based on linkage to the national death register) found that at 3 years on ART, corrected cumulative mortality was 12-15% [16, 17] compared with our uncorrected estimate of 10%. There is an urgent need to improve ascertainment of deaths in low-income and middle-income countries [18] [19] [20] .
Yet even with such underestimation, mortality is not the major reason for patient attrition in large ART programmes in developing countries. The greater threat to the success of the South African ART programme may be the observation of high levels of LTFU, insofar as this outcome reflects patients who have truly left care. The size and pace of ART scale-up may have contributed to observed LTFU. The programme has grown in size dramatically, with our combined cohort increasing enrolment 12-fold over 5 years. Such rapid increases have placed considerable strain on health services that were already overburdened [8, 16, 21] and may have undermined the programme's ability to monitor and retain patients in care. During 2007 alone, 33% of patients in this study were enrolled onto ART: compared with the 2002/2003 cohort of patients, they had a 12-fold higher risk of appearing LTFU. In addition, with longer duration on ART, observed LTFU accounted for an increasing proportion of overall programme attrition: from 9% at 6 months to 29% at 36 months on ART.
If the rapid expansion of ART services does increase observed LTFU, the situation may worsen as countries continue to expand access to HIV treatment. Based on 2002 WHO treatment guidelines, adult ART coverage in South Africa was an estimated 40% in 2008 [22] . In addition, the South African government recently revised its treatment guidelines to include all infected infants <1 year of age, pregnant women with CD4 cell counts of 350 cells/ml or less and patients co-infected with TB [23] . South Africa and many other countries in sub-Saharan Africa will need to continue to expand services while retaining large numbers of patients in care. This will require strengthening systems for chronic disease care in these countries [6] , where most health programmes are oriented towards episodic illnesses and acute care.
Successfully re-orienting health systems towards longterm chronic care will require a better understanding of the phenomenon of LTFU. Often viewed as a single construct, observed LTFU in an ART cohort more likely represents a range of patient outcomes including patients truly LTFU (i.e. lost to care) as well as those classified LTFU through administrative error or inadequate patient monitoring systems [15, 24] . In a situation of rapid scaleup of ART in resource-limited health systems, the ability to capture and report patient data may become increasingly inadequate [24] . Indeed, our results suggest that larger cohorts may have become more subject to these challenges in recent years. For example, the apparently sharp increase in observed LTFU among patients enrolled in 2007 is likely to reflect the cumulative burden of increasing patient numbers on both ART services and health informatics systems. This phenomenon may be particularly acute at larger and rapidly expanding ART sites, some of which enrolled up to 50% of their cumulative number of patients in 2007 alone.
Despite the scope of the problem of observed LTFU in ART services in southern Africa, relatively little is known about this phenomenon. These cohorts, which are largely Table 3 . Kaplan-Meier estimates of mortality, loss-to-follow-up and overall programme retention by duration of follow-up (n U 44 177 at baseline).
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Mortality Loss-to-follow-up Overall retention % (95% CI) % (95% CI) % (95% CI) funded by the national Department of Health, report active tracing (i.e. dedicated resources to undertake one or more of the following: telephone call, home followup, physician's report and/or data linkage) [3] . However, largely due to resource constraints, funding for patient follow-up, particularly at this scale, is limited. There is a small literature on factors associated with patient retention highlighting the possible role of patient preparation [25] , treatment supporters [26] , patient costs [10, 27] , improved databases [24] , community support [28] and simplified services [6] . However, research is needed to better understand observed LTFU and the relative contributions of true LTFU (patients dropping out of ART services) versus administrative LTFU (patients who are retained in care but appear LTFU due to problems with data capturing and reporting). In contrast to these individuals, patients who are truly LTFU are likely to be nonadherent to treatment and at higher risk of death [16, 29] . In addition, they face increased risk of drug resistance to ART, undermining the long-term effectiveness of treatment programmes [12, 16] . Additional research is needed into the programme-level determinants of LTFU, to better characterise patients classified LTFU and provide insights into patients' movements in and out of care.
This is the first report on outcomes from multiple cohorts in the world's largest antiretroviral therapy programme, and to our knowledge, the largest analysis of individuals starting ART in sub-Saharan Africa. It is strengthened by up to 5 years of patient follow-up on more than 40 000 patients. The results are likely generalizable to the patient population accessing public sector ART in most of South Africa [3] where 80% of the population rely on the public sector for services [30] . However, this analysis has several important limitations. As is the case with other largescale ART programmes based on routine monitoring and evaluation, it is constrained by issues of outcome ascertainment and missing data [24] . Outcome ascertainment should improve as more cohorts in South Africa link to the death register, presumably increasing observed mortality and decreasing observed LTFU. Data completeness is likely to present ongoing challenges, particularly as programmes continue to expand. WHO staging were the least complete data point in this analysis, yet the inclusion of staging in multivariate analysis impacted on the association between baseline CD4 cell count and outcomes, highlighting the importance of complete baseline data. Finally, this paper reports on averages across cohorts, which may differ in data quality, completeness and outcome ascertainment. Despite these constraints, this analysis utilizes routinely collected data to provide valuable insight into the effectiveness of a huge national programme, and has important implications for South Africa and for other programmes in similar contexts.
In summary, this analysis demonstrates that the South African national ART programme has undergone rapid scale-up over 5 years. While recorded mortality has declined, programme retention has deteriorated as decreasing patient mortality has been greatly offset by high and increasing levels of LTFU. This increased LTFU may represent true loss to care, but also may be due to increasing difficulty in monitoring patients enrolling into care as well as patient movements in and out of care. These possibilities require further investigation. Innovative, effective strategies are needed to follow and retain patients in large HIV treatment programmes while rapidly expanding access to ART services.
